BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 11991966)

  • 21. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
    Mungall BA; Xu X; Klimov A
    Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
    Govorkova EA; Fang HB; Tan M; Webster RG
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4855-63. PubMed ID: 15561867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
    Hurt AC; McKimm-Breschkin JL; McDonald M; Barr IG; Komadina N; Hampson AW
    Virus Res; 2004 Jul; 103(1-2):205-11. PubMed ID: 15163511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Farrukee R; Butler J; Reading PC; Hurt AC
    Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
    Ives JA; Carr JA; Mendel DB; Tai CY; Lambkin R; Kelly L; Oxford JS; Hayden FG; Roberts NA
    Antiviral Res; 2002 Aug; 55(2):307-17. PubMed ID: 12103431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201.
    Smee DF; Sidwell RW; Morrison AC; Bailey KW; Baum EZ; Ly L; Wagaman PC
    Antiviral Res; 2001 Dec; 52(3):251-9. PubMed ID: 11675142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.
    McKimm-Breschkin J; Trivedi T; Hampson A; Hay A; Klimov A; Tashiro M; Hayden F; Zambon M
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2264-72. PubMed ID: 12821478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
    Yen HL; McKimm-Breschkin JL; Choy KT; Wong DD; Cheung PP; Zhou J; Ng IH; Zhu H; Webby RJ; Guan Y; Webster RG; Peiris JS
    mBio; 2013 Jul; 4(4):. PubMed ID: 23860768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture.
    Colacino JM; Laver WG; Air GM
    J Infect Dis; 1997 Aug; 176 Suppl 1():S66-8. PubMed ID: 9240698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural studies of the resistance of influenza virus neuramindase to inhibitors.
    Smith BJ; McKimm-Breshkin JL; McDonald M; Fernley RT; Varghese JN; Colman PM
    J Med Chem; 2002 May; 45(11):2207-12. PubMed ID: 12014958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication.
    Kati WM; Montgomery D; Carrick R; Gubareva L; Maring C; McDaniel K; Steffy K; Molla A; Hayden F; Kempf D; Kohlbrenner W
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1014-21. PubMed ID: 11897583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
    Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9).
    Gaymard A; Charles-Dufant A; Sabatier M; Cortay JC; Frobert E; Picard C; Casalegno JS; Rosa-Calatrava M; Ferraris O; Valette M; Ottmann M; Lina B; Escuret V
    J Antimicrob Chemother; 2016 Nov; 71(11):3036-3045. PubMed ID: 27432605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.
    Staschke KA; Colacino JM; Baxter AJ; Air GM; Bansal A; Hornback WJ; Munroe JE; Laver WG
    Virology; 1995 Dec; 214(2):642-6. PubMed ID: 8553569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient.
    L'Huillier AG; Abed Y; Petty TJ; Cordey S; Thomas Y; Bouhy X; Schibler M; Simon A; Chalandon Y; van Delden C; Zdobnov E; Boquete-Suter P; Boivin G; Kaiser L
    J Infect Dis; 2015 Dec; 212(11):1726-34. PubMed ID: 25985905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en.
    Blick TJ; Sahasrabudhe A; McDonald M; Owens IJ; Morley PJ; Fenton RJ; McKimm-Breschkin JL
    Virology; 1998 Jun; 246(1):95-103. PubMed ID: 9656997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
    Thompson CI; Barclay WS; Zambon MC
    J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors.
    Sauerbrei A; Haertl A; Brandstaedt A; Schmidtke M; Wutzler P
    Med Microbiol Immunol; 2006 Jun; 195(2):65-71. PubMed ID: 16059699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
    Ilyushina NA; Seiler JP; Rehg JE; Webster RG; Govorkova EA
    PLoS Pathog; 2010 May; 6(5):e1000933. PubMed ID: 20523902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.